Bernadette Connaughton
CIK: 0001662521
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (18 total)
- Aug 10, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct1.6K shares at avg. $102.80$167K - Jul 1, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct625 shares at avg. $77.21$48K - Jul 1, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct1K shares at avg. $76.39$76K - Jun 17, 2026EDIT
Editas Medicine, Inc.
Award(A)DirectStock Option (right to buy)
51.7K shares- - Jun 1, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct1.6K shares at avg. $66.21$108K - May 5, 2026HALO
HALOZYME THERAPEUTICS, INC.
Award(A)Direct3.8K shares- - May 5, 2026HALO
HALOZYME THERAPEUTICS, INC.
Award(A)DirectOption to Purchase Common Stock
6K shares- - May 1, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct1.6K shares at avg. $63.48$103K - Jan 5, 2026HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct2K shares at avg. $70.25$141K - Dec 1, 2025HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct829 shares at avg. $71.60$59K - Nov 10, 2025HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct2K shares at avg. $68.48$137K - Oct 1, 2025HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct1.5K shares at avg. $75.09$113K - Oct 1, 2025HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct500 shares at avg. $75.70$38K - Sep 2, 2025HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct3K shares at avg. $73.62$219K - Sep 2, 2025HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct100 shares at avg. $71.71$7K - Sep 2, 2025HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct923 shares at avg. $74.11$68K - Jun 6, 2025EDIT
Editas Medicine, Inc.
Award(A)DirectStock Option (right to buy)
37.5K shares- - May 1, 2025HALO
HALOZYME THERAPEUTICS, INC.
Award(A)Direct4.2K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 10, 2026 |  HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 1,626 | $102.80 | $167,153 | Direct |
| Jul 1, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 625 | $77.21 | $48,256 | Direct |
| Jul 1, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 1,000 | $76.39 | $76,395 | Direct |
| Jun 17, 2026 |  EDIT Editas Medicine, Inc. | Award(A) Stock Option (right to buy) | 51,700 | - | - | Direct |
| Jun 1, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 1,625 | $66.21 | $107,591 | Direct |
| May 5, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Award(A) | 3,796 | - | $0 | Direct |
| May 5, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Award(A) Option to Purchase Common Stock | 6,040 | - | - | Direct |
| May 1, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 1,625 | $63.48 | $103,155 | Direct |
| Jan 5, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 2,000 | $70.25 | $140,500 | Direct |
| Dec 1, 2025 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 829 | $71.60 | $59,356 | Direct |
| Nov 10, 2025 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 2,000 | $68.48 | $136,960 | Direct |
| Oct 1, 2025 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 1,500 | $75.09 | $112,629 | Direct |
| Oct 1, 2025 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 500 | $75.70 | $37,852 | Direct |
| Sep 2, 2025 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 2,977 | $73.62 | $219,161 | Direct |
| Sep 2, 2025 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 100 | $71.71 | $7,171 | Direct |
| Sep 2, 2025 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 923 | $74.11 | $68,404 | Direct |
| Jun 6, 2025 | EDIT Editas Medicine, Inc. | Award(A) Stock Option (right to buy) | 37,500 | - | - | Direct |
| May 1, 2025 | HALO HALOZYME THERAPEUTICS, INC. | Award(A) | 4,165 | - | - | Direct |
1-18 of 18 transactions
About Connaughton Bernadette
Connaughton Bernadette (SEC CIK 0001662521) files insider reports with the SEC as Director of HALOZYME THERAPEUTICS, INC. (HALO) and Director of Editas Medicine, Inc. (EDIT).
Signal8 holds 14 ownership filings by Connaughton Bernadette, all Form 4s, filed between May 2, 2025 and Oct 8, 2026. Those filings report 18 transactions, from May 1, 2025 to Aug 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Connaughton Bernadette's filings is in SAN DIEGO, CA.
Recent filings by Connaughton Bernadette
- Aug 10, 2026: Open-market sale of HALO shares (Form 4, code S).
- Jul 1, 2026: Open-market sales of HALO shares (2 lines, Form 4, code S).
- Jun 17, 2026: Grant or award of EDIT derivative securities (Form 4, code A).
- Jun 1, 2026: Open-market sale of HALO shares (Form 4, code S).
- May 5, 2026: Grants or awards of HALO shares (2 lines, Form 4, code A).
Other insiders filing for HALOZYME THERAPEUTICS, INC. (HALO)
- Torley Helen, PRESIDENT AND CEO
- Daly James M, Director
- Posard Matthew L., Director
- Appelhans Dannielle, Director
- RAMSAY DAVID A, EVP, PRESIDENT, DRUG DELIVERY
- Snellgrove Darren, SVP, Chief Financial Officer